Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers enrolled participants within 14 days of their HIV diagnosis.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.
Researchers have presented 96-week results from an advanced trial of Symtuza compared with Prezcobix plus Truvada.
Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.
The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
An ongoing study is giving the regimen to those acutely infected with HIV, before waiting for results of resistance and other lab tests.
Janssen’s single-tablet antiretroviral regimen was approved on July 17.
A new large study compared the single-tablet regimen with an equivalent containing a different version of tenofovir.
Results from a Phase III trial showed Symtuza worked as well as a boosted protease inhibitor–based antiretroviral regimen.
The combo tablet contains Janssen’s darunavir and Gilead Sciences cobicistat, emtricitabine and tenofovir alafenamide.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.